|1.||Dunkle, Lisa M: 1 article (11/2015)|
|2.||Patriarca, Peter A: 1 article (11/2015)|
|3.||Cox, Manon M J: 1 article (11/2015)|
|4.||Bock, S Allan: 1 article (11/2015)|
|5.||Leffell, David J: 1 article (11/2015)|
|6.||Izikson, Ruvim: 1 article (11/2015)|
|7.||Post, Penny: 1 article (11/2015)|
|8.||McIntyre, Peter: 1 article (02/2012)|
|9.||Sheppeard, Vicky: 1 article (02/2012)|
|10.||Casacelli, Margot: 1 article (02/2012)|
11/27/2015 - "Flublok was non-inferior to AFLURIA in adults ≥50 years of age with respect to expert-adjudicated events of likely hypersensitivity during 30 days following vaccination (Sponsored by Protein Sciences Corporation; ClinicalTrials.gov number NCT01825200)."
11/27/2015 - "The adjudicators determined that six and four subjects on Flublok and AFLURIA, respectively, likely met clinical criteria for hypersensitivity, yielding a difference in incidence between the two vaccine groups of 0.15% (upper bound of 2-sided 95% CI=0.9%). "
11/27/2015 - "Fifty-two subjects reported at least one term possibly representing hypersensitivity, with a slight imbalance of 31 on Flublok and 21 on AFLURIA. "
11/27/2015 - "This blinded, randomized trial of healthy adults ≥50 years of age compared safety of Flublok vs. AFLURIA with respect to pre-specified possible hypersensitivity: "rash," "urticaria," "swelling" and "non-dependent edema;" solicited reactogenicity and unsolicited adverse events. "
11/27/2015 - "The safety and tolerability of Flublok(®), a purified recombinant hemagglutinin seasonal influenza vaccine, was compared to AFLURIA(®) in a randomized, blinded clinical trial in adults ≥50 years of age with attention to hypersensitivity reactions. "
|5.||Human Influenza (Influenza)
08/13/2010 - "An antigenically equivalent 2010-11 Northern Hemisphere seasonal influenza TIV (Afluria) manufactured by CSL Biotherapies is approved by the Food and Drug Administration (FDA) for persons aged >or=6 months in the United States. "
08/13/2010 - "If no other age-appropriate, licensed inactivated seasonal influenza vaccine is available for a child aged 5-8 years who has a medical condition that increases their risk for influenza complications, Afluria can be used; however, providers should discuss with the parents or caregivers the benefits and risks of Afluria use before administering this vaccine to children aged 5-8 years."
01/01/2010 - "Influenza (Afluria) and pneumococcal polysaccharides (Pneumo23) vaccines were given 6 months after rituximab (post-RTX group, n=11) or 6 days before rituximab treatment (pre-RTX group; n=8). "
|2.||Influenza Vaccines (FluMist)